Method to reduce an inflammatory response from arthritis

Details Method to reduce an inflammatory response from arthritis Method to reduce an inflammatory response from arthritis

2008-05-27

2008-05-27

Crane, L. E. (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S047000

Reexamination Certificate

active

07378400

ABSTRACT:
The present invention provides a therapeutic method for treating an inflammatory response caused by autoimmune stimulation, comprising the administration to a patient in need thereof of an antiinflammatory amount amount of an A2Aadenosine receptor agonist. The autoimmune stimulation can be caused by arthritis, particularly rheumatoid arthritis. Optionally, the method includes administration of a type IV PDE inhibitor.

REFERENCES:
patent: 3892777 (1975-07-01), Gruenman et al.
patent: 4012495 (1977-03-01), Schmeichen et al.
patent: 4193926 (1980-03-01), Schmiechen et al.
patent: 4242345 (1980-12-01), Brenner et al.
patent: 4665074 (1987-05-01), Amschler
patent: 4824660 (1989-04-01), Angello et al.
patent: 4879296 (1989-11-01), Daluge et al.
patent: 4938949 (1990-07-01), Borch et al.
patent: 4956345 (1990-09-01), Miyasaka et al.
patent: 4965271 (1990-10-01), Mandell et al.
patent: 4968697 (1990-11-01), Hutchison
patent: 5070877 (1991-12-01), Mohiuddin et al.
patent: 5096906 (1992-03-01), Mandell et al.
patent: 5124455 (1992-06-01), Lombardo et al.
patent: 5140015 (1992-08-01), Olsson et al.
patent: 5189027 (1993-02-01), Miyashita et al.
patent: 5272153 (1993-12-01), Mandell et al.
patent: 5278150 (1994-01-01), Olsson et al.
patent: 5298508 (1994-03-01), Jacobson et al.
patent: 5364862 (1994-11-01), Spada et al.
patent: 5561134 (1996-10-01), Spada et al.
patent: 5565462 (1996-10-01), Eitan et al.
patent: 5593975 (1997-01-01), Cristalli
patent: 5593976 (1997-01-01), Mongelli et al.
patent: 5665754 (1997-09-01), Feldman et al.
patent: 5668139 (1997-09-01), Belardinelli et al.
patent: 5696254 (1997-12-01), Mansour et al.
patent: 5731296 (1998-03-01), Sollevi
patent: 5756706 (1998-05-01), Mansour et al.
patent: 5776940 (1998-07-01), Daluge et al.
patent: 5854081 (1998-12-01), Linden et al.
patent: 5877180 (1999-03-01), Linden et al.
patent: 5932558 (1999-08-01), Cronstein et al.
patent: 5998386 (1999-12-01), Feldman
patent: 6004945 (1999-12-01), Fukunaga
patent: RE36494 (2000-01-01), Olsson et al.
patent: 6020321 (2000-02-01), Cronstein et al.
patent: 6020339 (2000-02-01), Perrier et al.
patent: 6034089 (2000-03-01), Han et al.
patent: 6060481 (2000-05-01), LaNoue et al.
patent: 6117878 (2000-09-01), Linden
patent: 6232297 (2001-05-01), Linden et al.
patent: 6303619 (2001-10-01), Linden
patent: 6322771 (2001-11-01), Linden et al.
patent: 6326359 (2001-12-01), Monaghan et al.
patent: 6332771 (2001-12-01), Adams et al.
patent: 6339072 (2002-01-01), Martin et al.
patent: 6350735 (2002-02-01), Monaghan
patent: 6387889 (2002-05-01), Endo et al.
patent: 6448235 (2002-09-01), Linden et al.
patent: 6514949 (2003-02-01), Linden et al.
patent: 6525032 (2003-02-01), Mantell et al.
patent: 6531457 (2003-03-01), Linden et al.
patent: 6545002 (2003-04-01), Linden et al.
patent: 6624158 (2003-09-01), Mantell et al.
patent: 6670334 (2003-12-01), Linden et al.
patent: 6936596 (2005-08-01), Konno et al.
patent: 7214665 (2007-05-01), Linden et al.
patent: 7226913 (2007-06-01), Linden et al.
patent: 2002/0032168 (2002-03-01), Mantrell et al.
patent: 2002/0058641 (2002-05-01), Mantell et al.
patent: 2003/0013675 (2003-01-01), Yeadon et al.
patent: 2003/0162742 (2003-08-01), Linden et al.
patent: 2005/0182018 (2005-08-01), Linden et al.
patent: 2005/0282831 (2005-12-01), Baeuglehole et al.
patent: 0488336 (1992-06-01), None
patent: 0700908 (1998-03-01), None
patent: 1150991 (2004-04-01), None
patent: 174074 (1979-10-01), None
patent: WO-93/22328 (1993-11-01), None
patent: WO-95/11681 (1995-05-01), None
patent: WO95/11681 (1995-05-01), None
patent: WO-96/02553 (1996-02-01), None
patent: WO96/02553 (1996-02-01), None
patent: WO-96/04280 (1996-02-01), None
patent: WO-98/47509 (1998-10-01), None
patent: WO-98/57651 (1998-12-01), None
patent: WO-98/57651 (1998-12-01), None
patent: WO-99/34804 (1999-07-01), None
patent: WO99/34804 (1999-07-01), None
patent: WO-99/38877 (1999-08-01), None
patent: WO-99/41267 (1999-08-01), None
patent: WO-99/62518 (1999-12-01), None
patent: WO-99/63938 (1999-12-01), None
patent: WO-99/67263 (1999-12-01), None
patent: WO-99/67264 (1999-12-01), None
patent: WO-99/67265 (1999-12-01), None
patent: WO-99/67266 (1999-12-01), None
patent: WO-00/44763 (2000-01-01), None
patent: WO-00/23457 (2000-04-01), None
patent: WO-00/72799 (2000-12-01), None
patent: WO-00/78774 (2000-12-01), None
patent: WO00/78774 (2000-12-01), None
patent: WO-00/78777 (2000-12-01), None
patent: WO-01/94368 (2001-12-01), None
patent: WO-02/09701 (2002-02-01), None
patent: WO02/09701 (2002-02-01), None
patent: WO-02/096462 (2002-12-01), None
patent: WO02/096462 (2002-12-01), None
patent: WO-03/014137 (2003-02-01), None
patent: WO-03/086408 (2003-10-01), None
Okusa et al., “Selective A2A Adenosine Receptor Activation Reduces Ischemia-Reperfusion Injury in Rat Kidney,” American J. Physiology: Heart and Circulatory Physiology, 277(3, Pt. 2), F404-F412 (Sep. 1999).
Peirce et al., “Selective A2A Adenosine Receptor Activation Reduces Skin Pressure Ulcer Formation and Inflammation,” American J. Physiology: Heart and Circulatory Physiology, 281(1, Pt. 2), H67-H72 (Jul. 2001).
Sullivan et al., “Cyclic AMP-Dependent Inhibition of Human Neutrophil Oxidation Activity by Substituted 2-Propynycyclohexyl Adenosine A2A Receptor Agonists,” British J. Pharmacology, 132(5), 1017-1026 (2001).
Beers et al. (eds.), The Merck Manual of Diagnosis and Therapy, 17th Edition, Merck & Co., Rahway, NJ, Jan. 1999, only pp. 924-925 supplied.
Venes et al. (eds.), Taber's Cyclopedic Medical Dictionary, 19th Edition, F. A. Davis, Philadelphia, PA, 2001, only pp. 960-961 supplied.
Ishiwata et al., “Further Characterization of a CNS Adenosine A2A Receptor Ligand [11C] KF18446 with in vitro Autoradiography and in vivo Tissue Uptake,” Annals on Nuclear Medicine, 14(2), 81-89 (2000).
Sullivan et al., “A2A Adenosine Receptor Activation Improves Survival in Mouse Models of Endotoxemia and Sepsis,” Journal of Infectioous Diseases, 189, 1897-1904 (May 15, 2004).
Moore et al., “A2A Adenosine Receptor Agonists Modify Inflammatory Responses in anE. coliPeritonitis Murine Septic Shock Model,” Abstract (###) from the 43rd Annual Meeting of the Infectious Disease Society of America, Oct. 6-9, 2005, San Francisco, California.
Hogan et al., “Inhibiting the Inflammatory Response in Joint Sepsis,” Arthroscopy, 17(3), 311-315 (Mar. 2001).
Abiru, T., et al., “Nucleosides and nucleotides. 107.2-(cycloalkylalkynyl)adenosines: adenosine A2 receptor agonists with potent antihypertensive effects”,Journal of Medicinal Chemistry,35(12), (Jun. 12, 1992),2253-2260.
Adah, S. A., “Synthesis of Complex Ethynyladenosines Using Organic Triflic Enolates in Palladium-Catalyzed Reactions: Potential Agonists for the Adenosine A2 Receptor”,Tetrahedron, 53, (1997),6747-6754.
Ali, H., et al., “Methylxanthines Block Antigen-induced Responses in RBL-2H3 Cells Independently of Adenosine Receptors or Cyclic AMP: Evidence for Inhibition of Antigen Binding to IgE”,Journal of Pharmacology and Experimental Therapeutics, 258, (1991),954-962.
Andersson, P., et al., “Anti-anaphylactic and anti-inflammatory effects of xanthines in the lung”,Curr. Clin. Pract. Ser., (1985),187-192.
Baraldi, Pier G., et al., “Synthesis and Biological Activity of a New Series of N6-Arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-Carboxamido derivatives of adenosine-5′-N-ethyluronamide as A1 and A3 Adenosine receptor agonists”,Journal of Medicinal Chemistry, 41(17), (Aug. 13, 1998),3174-3185.
Beers, Mark H., et al., “The Merck Manual of Diagnosis and Therapy”,Merck and CompanyJan. 1999, 924-925.
Berkich, D. A., et al., “Evidence of Regulated Coupling of A1 Adenosine Receptors by Phosphorylation in Zucker Rats.”,American Journal of Physiology, 268 (4), (Apr. 1995),E693-E704.
Bhattacharya, S., et al., “Effects of Long-Term Treatment With the Allosteric Enhancer, PD81,723, on Chinese Hamster Ovary Cells Expre

Affiliated with

Also associated with

Rating

Method to reduce an inflammatory response from arthritis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method to reduce an inflammatory response from arthritis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method to reduce an inflammatory response from arthritis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2786429